Abstract

**Purpose** Children with extensive lymphatic malformations of the head and neck often suffer from functional impairment and aesthetic deformity which significantly affect the quality of life and may be life-threatening. Treatment with sirolimus has the potential to improve symptoms and downsize lymphatic malformations. This systematic review summarizes the current information about sirolimus treatment of lymphatic malformations of the head and neck in children, its efficacy and side effects.

**Methods** A systematic search of the literature regarding studies on sirolimus treatment of children with lymphatic malformations of the head and neck was performed in PubMed, Embase, and Google Scholar up to July 2021 with the search terms “lymphatic malformation”, “lymphangioma”, “cystic hygroma”, “low-flow malformation”, “sirolimus”, “rapamycin”, “mTOR inhibitor” and “children”.

**Results** In all, 28 studies including 105 children from newborn to 17 years treated with sirolimus for lymphatic malformations of the head and neck were analyzed. The most frequent initial dose was 0.8 mg/m² per dose, twice daily at 12-h interval. The target blood level differed between studies, 10–15 ng/mL and 5–15 ng/mL were most often used. More than 91% of the children responded to sirolimus treatment which lasts from 6 months to 4 years. Typical side effects were hyperlipidemia, neutropenia and infections.

**Methods** Sirolimus could be an effective treatment for children with large complicated lymphatic malformations of the head and neck. As not all patients will benefit from treatment, the decision to treat sirolimus should be made by a multidisciplinary team.

**Keywords** Lymphatic malformation · Children · Sirolimus · Rapamycin
possible sclerosants, however, picibanil (OK-432) and doxycycline are most often used [6]. Laser therapy to vaporize the tissue and seal superficial lymphatic channels is mainly effective in mucosal LM. In absence of functional deficits and symptoms watch-and-wait may also be an option. Pharmacologic treatment with different drugs has also been considered for the treatment of large LM, especially in patients who were refractory to conventional treatments. The most promising systemic treatment seems to be sirolimus that was demonstrated to be useful in the therapy of certain diseases and has been shown to inhibit lymphangiogenesis [7–10].

Sirolimus is also known as rapamycin, as it was initially discovered in a soil sample of Rapa Nui (Easter Island). It is a natural macrolide derived from the soil bacteria Streptomyces hygroscopicus. Sirolimus is a specific inhibitor of the mammalian target of rapamycin (mTOR), a serine/threonine kinase that is a key factor in the regulation of angiogenesis, cell growth and proliferation. Sirolimus was approved by the FDA in 1999 as an oral immunosuppressive for use in renal transplantation and in 2015 as the first drug to treat lymphangioleiomyomatosis, a rare disease that is characterized by progressive, cystic lung disease, angiomyolipoma and lymphangioleiomyomas and predominately affects young women. Owing to its antiangiogenic and antiproliferative properties, sirolimus treatment was used to treat large LM. In a previous systematic review, it could be demonstrated that treatment with sirolimus has the potential to improve symptoms and downsize LM of different body areas [11]. The present review aims to analyze the available information about efficacy and side effects in children with LM of the head and neck.

**Material and methods**

A systematic search of the literature was performed in PubMed, Embase, and Google Scholar. The search terms “lymphatic malformation”, “lymphangioma”, “cystic hygroma”, “low-flow mal-formation”, “sirolimus”, “rapamycin”, “mTOR inhibitor” and “children” were used in “AND” and “OR” combinations. The search was limited to articles published until July 2021. All studies focusing on systemic sirolimus therapy for head and neck LM in children (<18 years) that were presented in English, Spanish, French and German languages were eligible for inclusion. Studies reporting non-original data (systematic reviews, meta-analyses, narrative reviews, commentaries, correspondence, letters), studies addressing both adults and children or LM of locations inside and outside the head and neck and that did not report data from the head and neck or children separately, duplicate publications, as well as reports with insufficient information were excluded. Reports on topical treatment were also excluded. In addition to the electronic database search, the reference sections of previous systematic reviews and the included articles were checked for further potentially relevant articles. The literature search and the evaluation of inclusion criteria were performed by the first author with uncertainties resolved through consultation among all the authors. The initial screening was based on the titles and/or abstracts. Next, the hard copies of the potentially eligible publications were examined to assess whether they met the inclusion criteria. Reports on the generalized lymphatic anomaly, Gorham-Stout disease, lymphangiomatosis, lymphangiectasia, and chronic lymphedema as well as studies on patients with venolymphatic and capillary-lymphaticovenous malformations were not included in this review.

For each selected report, the following variables were considered: year and country of publication, study design, number of cases described, sex and age of the patients, location of LM, treatment (including dosage and target serum level), treatment duration, outcome, adverse events and follow-up.

**Results**

**Clinical characteristics of the patients**

In all, 28 case series and case reports and two prospective trials [31, 36] including 105 children treated with sirolimus for LM of the head and neck, were included in this review (Table 1) [12–39]. Due to the inclusion criteria, the age of the patients ranged from newborn to 17 years. The male to female ratio was 1:1:21, but the sex was not reported for all patients. In 51 patients (48.6%), pretreatment using other modalities was reported to be insufficient without adequate response. The most common pretreatments were sclerotherapy (n = 30), surgery (n = 7) and the combination of surgery and sclerotherapy (n = 7). Other pretreatments were intravenous triamcinolone, steroids combined with propranolol, sildenafil and propranolol, prednisone, laser therapy as well as surgery combined with laser therapy.

**Treatment with sirolimus**

In most studies, sirolimus was administered orally at an initial dosage of 0.8 mg/m² per dose, twice daily at 12-h intervals [13, 17, 19, 21, 23–26, 28, 34, 36, 39]. In other studies, this was modified to 0.8 mg/m² per day [29], 0.8 mg per day in three doses [32], or 0.08 mg/kg per day [30]. Zhang reported to use a reduced starting dose in neonates (0.5 mg/m²). Other starting doses were 1–2 mg per day [31], 0.1 mg/kg per day [35], 0.05 mg/kg twice daily [16], 0.6 mg/m² per twice daily dose [33], 0.07 mg/kg twice daily [18], 0.4–0.8 mg/m² twice daily [20] or in two fractions [27], and
| Author          | Year | No. of patients | Localization                                                                 | Age          | Sex | Starting dose                                                                 | Target blood level (ng/mL) | Parallel treatment | Result       | Therapy duration | Adverse events                                  |
|-----------------|------|-----------------|------------------------------------------------------------------------------|--------------|-----|-------------------------------------------------------------------------------|----------------------------|-------------------|--------------|-----------------|-------------------------------------------------|
| Tschauner [12]  | 2013 | 4               | Neck                                                                         | 6 Mo-4 Y     | F   | NR                                                                            | NR                         | No                | PR (49–75%) | NR              | NR                                              |
| Akyüz [13]      | 2014 | 1               | Tongue                                                                       | 10 Y         | M   | NR                                                                            | NR                         | No                | PR (70%)     | 12 Mo           | NR                                              |
| Margolin [14]   | 2014 | 1               | Neck, tongue, mediastinum, floor of mouth                                   | 17 Mo        | F   | NR                                                                            | 10–15                      | No                | PR           | 12 Mo (ongoing) | NR                                              |
| Alemi [15]      | 2015 | 2               | Larynx, neck, mediastinum, face, neck, chest wall, larynx, mediastinum, oropharynx | 4 Mo, 1 Mo   | M   | NR                                                                            | NR                         | Laser surgery     | PR           | 2y, 8 mo discontinued, 5 mo (ongoing) 11 mo (ongoing) | No                                              |
| Lackner [16]    | 2015 | 1               | Orbit                                                                        | 9 Y          | M   | 0.05 mg/kg given twice daily                                                  | 5–15                       | No                | PR           | 6 Mo            | Mild reversible leukopenia                      |
| Yesil [17]      | 2015 | 1               | Tongue                                                                       | 1 Y          | F   | 0.8 mg/m² per dose twice daily                                                | 10–15                      | No                | PR (90%)     | 9 Mo            | Hypertriglyceridemia                            |
| Azouz [18]      | 2016 | 1               | Neck, cheek, tongue                                                          | 1 Mo         | M   | 0.07 mg/kg given twice daily                                                  | NR                         | No                | PR           | 15 mo           | NR                                              |
| Altawil [19]    | 2017 | 2               | Neck                                                                          | 20 Mo, 12 Y  | F   | 0.8 mg/m² per dose twice daily                                                | 10–13                      | No: 1 sclerotherapy: 1 | 2 PR         | 6 weeks (ongoing) 8 weeks (ongoing)  | Neutropenia (2)                                      |
| Amodeo [20]     | 2017 | 3               | Face, neck, upper mediastinum                                                 | 2.5 Mo, 16 Mo | M, F | 0.4–0.8 mg/m² per dose twice daily                                            | 10–15                      | No: 2 surgery: 1 | 2 PR         | 1 > 6 Months 1 > 2 Months NR | Dyslipidemia (1)                                    |
| Escoda [21]     | 2017 | 1               | Neck                                                                          | Newborn       | M   | 0.8 mg/m² per dose twice daily                                                | 4–8                        | No                | PR           | 2 Mo (ongoing) | Hypertriglyceridemia, hypercholesterolaemia, nausea, vomiting |
| Thirion [22]    | 2017 | 2               | Retroorbital cervical                                                        | 2 Mo, 12 Years | M   | NR                                                                            | NR                         | No                | 2 PR         | 10 Mo (ongoing) 2y (ongoing) | No                                              |
| Author                  | Year | No. of patients | Localization                                      | Age            | Sex   | Starting dose | Target blood level (ng/mL) | Parallel treatment | Result | Therapy duration | Adverse events                                                                 |
|-------------------------|------|-----------------|---------------------------------------------------|----------------|-------|---------------|-----------------------------|--------------------|--------|------------------|--------------------------------------------------------------------------------|
| Strychowsky [23]        | 2018 | 15              | Cervicofacial                                     | 2 Mo–17 Y      | NR    | 0.8 mg/m² per dose twice daily | 10–15           | No                | 15 PR  | 0.64Y–3.42Y     | 4 patients ongoing (1.55–2.98 Y) Cellulitis (6) Nausea/emesis (3) Eczema (6) Mouth sores (9) Transaminitis (5), elevated cholesterol and triglycerides (4) Neutropenia (3) Rash (1) Acne (1) Diarrhea (1) Headache (3) Alopecia (1) Irregular menstrual bleeding (1) |
| Hammer [24]             | 2018 | 3               | Cervicofacial, larynx, parotid, tongue, retroorbital | 3y, 11y, 16y, 1M | 2 F   | 0.8 mg/m² per dose twice daily | 10–15           | No                | 2 PR   | 13 Mo, 34 Mo     | 28 Mo ongoing Several, not only reported for LM |
| Triana [25]             | 2019 | 6               | FACE, NECK, TONGUE, SUBMANDIBULAR REGION          | Median 15D (1–32 D) | 3 F, 3 M | 0.8 mg/m² per dose twice daily | 4–12            | No                | 1 CR   | 3–46 Mo          | Elevation of gamma-glutamyl transferase (1) and triglycerides (1) lymphangitis (3), intralesional bleeding (2) |
| Curry [26]              | 2019 | 1               | Neck, upper chest                                | 22 D           | F     | 0.8 mg/m² per dose twice daily | 10–15           | No                | PR     | 8 Mo, ongoing    | Cellulitis |
| Ghariani Fetoui [27]    | 2019 | 1               | Tongue                                           | 2 Y            | F     | 0.4–0.8 mg/m²/d in two divided doses | 10–12           | No                | PR     | 6 Mo             | Bacterial pneumonia |
| Gimenez-Alexandre [28]  | 2019 | 3               | Neck, cervicofacial, retroorbital                | 2 Mo, 4 Y, 13 Y | f     | 0.8 mg/m² per dose twice daily | 5–15            | No                | 1 PR   | 10mo ongoing     | Hypertransaminasemia (1) hypercholesterolemia (1) |
| Gonzalez-Hermosa [29]   | 2019 | 1               | Cervical                                         | 19 D           | m     | 0.8 mg/m² per day                | NR              | No                | PR after 12 months | 16 Mo           | No |
### Table 1 (continued)

| Author              | Year | No. of patients | Localization                      | Age             | Sex | Starting dose | Target blood level (ng/mL) | Parallel treatment                          | Result            | Therapy duration | Adverse events                                                                 |
|---------------------|------|-----------------|-----------------------------------|-----------------|-----|---------------|----------------------------|----------------------------------------------|-------------------|------------------|--------------------------------------------------------------------------------|
| Meurisse [30]       | 2019 | 2               | Neck                              | 21 D 9 weeks    | 1 m, 1 NR | 0.08 mg/kg/day | 3.5–6 4–12                | Sclero-therapy with polidocanol or ethanol gel | PR (70% and 80%) | 8–16 Mo          | No                                                                            |
| Ozeki [31]          | 2019 | 5               | Neck, tongue, Orbit, mediastinal  | 2 weeks, 10 mo, 1 y, 2 y, 11 y | 2 m, 3 f | 1-2 mg once a day | 5–15                       | No                                                          | 4 PR 1 SD         | 6–18 Mo          | Upper respiratory infection (1), cellulitis (1), stomatitis (1)               |
| Pandey [32]         | 2019 | 16              | Tongue                            | 0–12 y          | NR  | 0.8 mg/day in three doses | NR                         | No                                                          | 14 PR (9 > 75%, 5 > 50%) | NR               | NR                                                                            |
| Sandbank [33]       | 2019 | 3               | Cervicofacial, tongue             | NR              | NR  | 0.6 mg/m² per dose twice daily | 5–12                       | No                                                          | 3 PR NR           | NR               | Hyperkalaemia, hypercholesterolemia, increased AST                             |
| Gomez-Sanchez [34]  | 2020 | 3               | Cervicofacial, supraglottic and pharyngeal parotid | 3 Y, 8 Y, 9 Y M | 0.8 mg/m² per dose twice daily | 5–15                       | No                                                          | PR: 3 4 Y ongoing | 4 Y ongoing | Slight cholesterol increase (1), oral enanthema (1)                         |
| Honnorat [35]       | 2020 | 1               | Cervicofacial                      | 1 D F           | 0.1 mg per kg per day | 12–20                       | Sclero-therapy with doxycycline and bleomycin, laser therapy | PR              | 9 Mo ongoing       | Mild dyslipidaemia, several infections                                      |
| Zhang [36]          | 2021 | 16              | Neck                              | 16 D–171 Mo NR  | 0.8 mg/m² per dose twice daily | 4–13                       | No                                                          | PR: 14 NR         | NR               | Oral mucositis, hypercholesterolemia, upper respiratory infections, hepatic dysfunction, dizziness, cystic hemorrhage |
| Chouchene [37]      | 2021 | 1               | Tongue                            | 2 Y F           | 1.5 mg/kg/day in two divided daily doses | NR                         | No                                                          | PR               | 6 Mo             | No                                                                            |
Table 1 (continued)

| Author  | Year | No. of patients | Localization     | Age   | Sex | Starting dose | Target blood level (ng/mL) | Parallel treatment | Result   | Therapy duration | Adverse events                                                                 |
|---------|------|-----------------|------------------|-------|-----|---------------|-----------------------------|-------------------|----------|------------------|--------------------------------------------------------------------------------|
| Harbers [38] | 2021 | 1               | Tongue           | 1 Y   | F   | NR            | 4–10                        | Surgery           | PR       | 6 Mo, interruption, restart for 15 mo, surgery, restart, in all 41 mo, ongoing | Intermittent aphthous stomatitis, upper airway infections, tonsillitis, elevation of triglycerides |
| Wu [39]  | 2021 | 8               | Head and neck    | 2 Mo-3 Y | 5 F, 3 M | 0.8 mg/m², twice-a-day | 10–15                       | –                  | At the final observation (12 months) PR: 40% (3), 60% (3), 75% (1), 10% (1) | 1.11–1.65y, ongoing Mouth sores (6), eczema (1), gastrointestinal reaction (2), dyslipidemia (1), neutropenia (1) One patient interrupted sirolimus therapy for recurrent fever caused by upper respiratory tract infection |

Abbreviations: y year, mo months, d days, m male, f female, NR not reported, NE not evaluable, PR partial response, PD progressive disease
1.5 mg/kg/day administered in two divided daily doses [37]. In five publications, the initial dose of sirolimus was not reported [12, 14, 15, 22, 38]. After the beginning of treatment with sirolimus the dose was then subsequently adjusted to reach the planned target blood level.

The target blood level of sirolimus was ≤ 20 ng/mL in all studies but slightly differed. The target blood level was 10–15 ng/mL in seven studies [14, 17, 20, 23, 24, 26, 39], 5–15 ng/mL in four studies [16, 28, 31, 34] and 4–12 ng/mL in two studies [25, 30]. In one study each, 3.5–6 ng/mL [30], 4–8 ng/mL [21], 4–10 ng/mL [38], 4–13 ng/mL [36], 5–12 ng/mL [33], 10–12 ng/mL [27], 10–13 ng/mL [19] and 12–20 ng/mL [35] were the target concentrations. Eight studies did not report the target blood level of sirolimus [12, 13, 15, 18, 22, 29, 32, 37]. Not in all studies the planned target trough level for sirolimus was achieved [14, 20]. For example, Margolin et al. [14] reported that the sirolimus level was often < 2 ng/mL. Despite difficulties with maintaining the desired sirolimus levels, there was a significant reduction in LM size in the presented case [14].

The time-to-response was not reported in all studies and seem to be variable. For example, Azouz et al. reported a reduction of 70–80% of the LM after 10 days of treatment [18]. Akyüz et al. [13] and Yesil et al. [17] reported a decrease in size of 60% and 70% after 3 months, respectively. Gomez-Sanchez et al. [34] reported a clinical response time from 3.5 to 9 months, Amodeo et al. [20] reported about a response after two months of treatment, while Gonzalez-Hermosa et al. [29] reported 13 months.

In 24 studies, data on the duration of treatment were presented [13–31, 34, 35]. The duration of sirolimus treatment ranged from 6 months to 4 years. In many patients, sirolimus treatment was ongoing at the time of the report.

Parallel treatments additionally to sirolimus were performed in seven cases (6.7%) [15, 19, 20, 30, 35, 38]. In one patient sirolimus was combined with sclerotherapy and laser therapy [35], in two patients with surgery [20, 38], in one patient with laser surgery [15], and in three patients with sclerotherapy [19, 30].

**Treatment efficacy**

In all, 96 children (91.4%) responded to sirolimus treatment. 95 patients had a partial response, in one neonate a complete response was reported [25]. This neonate with a large macrocystic cervicofacial LM was treated with sirolimus from the 15th day of life for twelve months. Due to a total involution of the LM at 12 months of life treatment was stopped. There was no recurrence one year later.

In many trials, the volume reduction was not quantified. Terms like “marked improvement”, “significant volume reduction” or “significant decrease” were used. For this reason, a comparison of the results is only possible to a limited extent. In those studies, were the percentage of volume reduction was reported, the reductions were between 49 and 90% [12, 13, 17, 30, 32]. Independent of the decrease of LM, Hammer et al. reported an improvement in pain in all patients [24].

**Side effects**

Twenty-three studies commented on possible adverse events associated with and probably being a result of sirolimus therapy [15–17, 19–31, 33–39]. In five studies no patients experienced side effects [15, 22, 29, 30, 37]. In the other 18 studies, different adverse effects were reported [16, 17, 19–21, 23–28, 31, 33–36, 38, 39], the most common were hyperlipidemia, neutropenia and infections such as cellulitis. There was no reporting of adverse events graded according to Common Terminology Criteria for Adverse Events (CTCAE). In three studies [23, 27, 36] sirolimus was interrupted or stopped in some cases due to adverse events. For example, Strychowsky et al. described two patients who interrupted sirolimus therapy for adverse events, in one case intravenous antibiotics were given, the other 13-year-old patient developed alopecia but chose to resume sirolimus 4 months after stopping [23]. Zhang et al. reported that sirolimus was intermittently interrupted due to drug side effects in some cases. The adverse events did not correlate with the blood level of sirolimus [36].

In 46 patients (43.8%) from five studies [22, 23, 31, 32, 34] a prophylactic administration of sulfamethoxazole-trimethoprim for prevention of *Pneumocystis pneumonia* infection was performed. Occurrence of bacterial pneumonia during sirolimus therapy was only reported in one of all investigated cases [27], the causative bacterium was not reported. The sirolimus therapy was withheld in this case, and the girl was treated with a 2-week course of imipenem [27].

**Discussion**

Although it is an off-label use, sirolimus has been used for the treatment of vascular anomalies for more than a decade [40, 41] and there is a growing evidence on the effective role of sirolimus in treating LM. In the presented analysis, 90% of the children with LM of the head and neck responded to sirolimus. Besides volume reduction, pain relief and mucosal and skin changes were described. Despite the availability of molecular data demonstrating the impact of sirolimus on various intracellular signaling pathways, the mechanism of action of sirolimus in LM is—also due to the limited understanding of the biology and genetics of LM—not completely understood. The response to sirolimus seems to depend on the microvessel density within
the LM suggesting an interference with angiogenetic and lymphogenetic growth factor signaling pathways. Pandey et al. [32] demonstrated that mean lymphatic microvessel density, which was calculated immunohistochemically using the monoclonal antibody D2-40 as the lymphatic endothelial marker, was significantly different in good responders, partial and non-responders to sirolimus. Therefore, they concluded that lymphangiogenesis is a valuable predictive biomarker for the therapeutic response to sirolimus in children with LM [32]. Hori et al. [42] analyzed the activation of the mTOR pathway in a subset of lymphatic anomalies in vivo and demonstrated that normal lymphatic vessels expressed neither mTOR nor its phosphorylated form p-mTOR. In contrast to normal lymphatic vessels, endothelial cells of LM, kaposiform lymphangiomatosis and kaposiform hemangioendothelioma expressed mTOR. An activation of mTOR was seen in kaposiform lymphangiomatosis and kaposiform hemangioendothelioma but not in LM, whereas the activation of the ribosomal S6 kinase 1 (S6K1, an indicator of activated mTOR signaling), and the eukaryotic translation initiation factor 4E-binding protein (4EFP1) which mediate an increase in protein synthesis and cell growth in lymphangiogenesis was seen in all cases of kaposiform lymphangiomatosis and kaposiform hemangioendothelioma and 40% of LM. Although sirolimus is effective in LM, most of the LM were negative for its phosphorylated form p-mTOR. Hori et al. explained this fact by possible dual inhibition of mTOR and vascular endothelial growth factor (VEGF) pathway by sirolimus in lymphatic anomalies which both play a vital role in lymphangiogenesis [42, 43]. They assumed that sirolimus may inhibit lymphangiogenesis at least in part by downregulating VEGF expression in p-mTOR negative cases [42] as it was previously demonstrated that sirolimus treatment also inhibited the expression of VEGFR-3 and VEGF-C, the potent growth factors for lymphatic endothelial cells [44, 45]. However, prospective randomized trials concerning this issue are lacking.

Strychowsky et al. [23] reported that macrocystic LM may respond better than mixed or microcystic LM, and younger patients may respond better than older patients to sirolimus. It could be demonstrated that sirolimus can be well-tolerated even in preterm children [35]. It is unclear if there is variable efficacy of sirolimus treatment during different developmental time periods. Pre-treated patients seem to respond less well [23] but there may be synergistic effects with other treatments like sclerotherapy or surgery [18].

The duration of sirolimus treatment differed between the analyzed studies. Most children were treated for several months and sirolimus was not withdrawn at last follow-up. Freixo et al. [46] demonstrated for vascular anomalies that 75% of the first clinical response was reported in less than 21 days. In this review, the time to (reported) clinical response varied between 10 days [18] and 13 months [29]. However, the time to reach the optimum treatment effect remains unclear.

The ability to measure serum levels of sirolimus makes sirolimus treatment controllable to a certain extent. However, a serum level for an effective and safe treatment has not been defined so far. The optimal doses and corresponding plasma levels for each patient to achieve response are still not defined. The target levels, however, were most frequently 5 to 15 ng/mL. Most authors maintained sirolimus at the standard dose. Some authors recommend to reduce the dose after response to sirolimus reached a plateau for some months [23, 25] to achieve the minimal effective dose for each patient to remain asymptomatic. Also, after discontinuation of the drug, some patients had stable disease.

The off-label use of sirolimus in children with LM requires a thoughtful risk–benefit analysis and careful follow-up. Children treated with sirolimus for LM may be at a significant risk for severe adverse events and therefore should be monitored carefully. A retrospective chart review in different European centers demonstrated that most serious adverse events were observed in the first year of sirolimus therapy; but serious adverse events can also occur after a longer treatment period [41]. The occurrence of serious adverse events during sirolimus treatment did not seem to be dependent on the sirolimus blood level [41].

One infrequent but severe side effect is Pneumocystis Jiroveci pneumonia, which was reported in patients who underwent solid organ transplants and two patients with vascular anomalies treated with sirolimus [47–49]. Therefore, prophylaxis with sulfamethoxazole-trimethoprime is recommended by some authors [22, 23, 31, 32, 34, 41]. In the presented patient group, nearly half of the children received prophylactic antibiotic treatment with sulfamethoxazole-trimethoprime [22, 23, 31, 32, 34]. However, anti-infectious prophylactic measures were not standardized as data are lacking. Occurrence of bacterial pneumonia during sirolimus therapy was only reported in one of the presented patients [27], however, the causative bacterium was not reported. It is suspected that higher levels of sirolimus or concomitant medications such as corticosteroids may be a risk factor for Pneumocystis pneumonia [25] and therefore selected patients may benefit from Pneumocystis prophylaxis while on sirolimus.

This systematic review is not without limitations. Inherent to the design we have to deal with missing data which could have impacted the results. We observed a lack in standardization in reporting and its comprehensiveness as relevant details often were missing. In many studies, outcome measures were qualitative and not quantitative, moreover, the outcome was reported at different timepoints. There were variations in the age of the patients and treatment phases (with/without prior treatment), clinical management and treatment durations. The methodological quality
of the included studies is low and there was a heterogeneity regarding drug dosage, definition of response, measurement of response and measurement of toxicity. Finally, there may be publication bias with respect to centers publishing good outcomes.

**Conclusion**

Sirolimus could be an effective treatment in children with large complicated LM of the head and neck. Until now, data are lacking to define the optimal place of sirolimus in the management strategy. Patients and their parents should be well educated on potential adverse effects and the decision for sirolimus treatment should be made by a multidisciplinary team. However, not all patients benefit from treatment. Therefore, it will be important to define factors predicting response to sirolimus treatment and patients who will benefit from sirolimus. Possibly, the expression of key components of the mTOR signaling pathway (S6K1) and VEGF C and VEGFR3 can serve as a biomarker predicting treatment success. There is a need for further clinical trials in children with head and neck LM establishing the perfect timepoint for initiation and the duration of sirolimus treatment and optimal doses, which will likely depend on the phenotype and extension of the LM, the age of the child and the symptoms.

**Funding** Open Access funding enabled and organized by Projekt DEAL.

**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

**References**

1. Kennedy TL, Whitaker M, Pellitteri P, Wood WE (2001) Cystic hygroma/lymphangioma: a rational approach to management. Laryngoscope 111:1929–1937
2. Wiegand S, Eivazi B, Barth PJ, von Rautenfeld DB, Folz BJ, Mandic R, Werner JA (2008) Pathogenesis of lymphangiomas. Virchows Arch 453:1–8
3. Brouillard P, Boon L, Vikkula M (2014) Genetics of lymphatic anomalies. J Clin Invest 124:898–904
4. Wiegand S, Ott A, Zimmermann AP, Wilhelm T, Eivazi B, Werner JA (2013) Localization of lymphatic malformations of the neck. Lymphat Res Biol 11:101–103
5. Wiegand S, Eivazi B, Zimmermann AP, Neff A, Barth PJ, Sesterhenn AM, Mandic R, Werner JA (2009) Microcystic lymphatic malformations of the tongue-diagnosis, classification, and treatment. Arch Otolaryngol Head Neck Surg 135:976–983
6. Wiegand S, Eivazi B, Zimmermann AP, Sesterhenn AM, Werner JA (2011) Sclerotherapy of lymphangiomas of the head and neck. Head Neck 33:1649–1655
7. Swarbrick AW, Frederiks AJ, Foster RS (2021) Systematic review of sirolimus in dermatological conditions. Australas J Dermatol. https://doi.org/10.1111/ajd.13671
8. Selvarani R, Mohammed S, Richardson A (2021) Effect of rapamycin on aging and age-related diseases-past and future. Geroscience. 43(3):1135–1158. https://doi.org/10.1007/s11357-020-00274-1
9. Ventura-Aguirar P, Campistol JM, Diekmann F (2016) Safety of mTOR inhibitors in adult solid organ transplantation. Expert Opin Drug Saf 15(3):303–319. https://doi.org/10.1517/14740338.2016.1132998
10. McKeage K, Murdoch D, Goa KL (2003) The sirolimus-eluting stent: a review of its use in the treatment of coronary artery disease. Am J Cardiovasc Drugs 3(3):211–230. https://doi.org/10.2165/00129784-20030303-00007
11. Wiegand S, Wichmann G, Dietz A (2018) Treatment of lymphatic malformations with the mTOR inhibitor sirolimus - a systematic review. Lymphat Res Biol 16(4):330–339
12. Tschauner S, Sorantin E, Haxhija E (2013) Überprüfung systemischer Sirolimus-Therapie zystischer Lymphangiome mittels MRT – Methodenbeschreibung anhand von vier klinischen Fällen. Fortschr Röntgenstr 185-V07
13. Akyüz C, Ataş E, Varan A (2014) Treatment of a tongue lymphangioma with sirolimus after failure of surgical resection and propranolol. Pediatr Blood Cancer 6:931–932
14. Margolin JF, Soni HM, Pimpalwar S (2014) Medical therapy for pediatric vascular anomalies. Semin Plast Surg 28:79–86
15. Alemi AS, Rosbe KW, Chan DK, Meyer AK (2015) Airway response to sirolimus therapy for the treatment of complex pediatric lymphatic malformations. Int J Pediatr Otorhinolaryngol 79:2466–2469
16. Lackner H, Karastanueva A, Schwinger W, Benesch M, Sovinz P, Seidel M, Sperl D, Lanz S, Haxhija E, Reiterer F, Sorantin E, Urban CE (2015) Sirolimus for the treatment of children with various complicated vascular anomalies. Eur J Pediatr 174:1579–1584
17. Yesil S, Bozkurt C, Tanyildiz HG, Tekgunduz SA, Candir MO, Toprak S, Sahin G (2015) Successful treatment of macroglossia due to lymphatic malformation with sirolimus. Ann Otol Rhinol Laryngol 124:820–823
18. Azouh H, Salah H, Al-Ajlan S, Badran M (2016) Treatment of cystic hygroma in a young infant through multidisciplinary approach involving sirolimus, sclerotherapy, and debulking surgery. JAAAD Case Rep 2:350–353
19. Altwaiw L, Neel NF, Alhedayni A, Badran M, Alokaili R, AlAjlan S (2017) Neutropenia in sirolimus treated patients of lymphatic malformation: a case series. J Case Rep 7:169–173
20. Amodeo I, Colmaghi M, Raffaeli G, Cavallaro G, Ciralli F, Bangi S, Leva E, Pignataro L, Borzani I, Pugni L, Mosca F (2017) The use of sirolimus in the treatment of giant cystic lymphangioma: Four case reports and update of medical therapy. Medicine (Baltimore) 96(51):e8871. https://doi.org/10.1097/MD.0000000000008871
21. Escoda AC, Ramos ML, Suárez JA, Celma MS, Heredia AC, Passinich VPC (2017) Use of sirolimus in a newborn affected by lymphatic malformation. Eur J Hosp Pharm 24:130–131
22. Thirion S, Jamblin P, Demarche M, Boon L, Thiry A, Hoyoux C (2017) A new treatment for vascular anomalies: Six cases treated with rapamycin. Arch Pediatr. 24(7):600–606. https://doi.org/10.1016/j. arcped.2017.04.001

23. Strychowsky JE, Rahbar R, O’Hare MJ, Irace AL, Padua H, Trenor CC 3rd (2018) Sirolimus as treatment for 19 patients with refractory cervicofacial lymphatic malformation. Laryngoscope 128(1):269–276

24. Hammer J, Seront E, Duez S, Dupont S, Van Damme A, Schmitz S, Hoyoux S, Chopinet C, Clapuyt P, Hammer F, Vikkula M, Boon LM (2018) Sirolimus is efficacious in treatment for extensive and/or complex slow-flow vascular malformations: A monocentric prospective phase II study. Orphanet J Rare Dis 13(1):191. https://doi.org/10.1186/s13023-018-0934-z

25. Triana P, Miguel M, Díaz M, Cabrera M, López Gutiérrez JC (2019) Oral sirolimus: an option in the management of neonates with life-threatening upper airway lymphatic malformations. Lymphat Res Biol 17(5):504–511. https://doi.org/10.1089/lrb.2018.0068

26. Curry S, Logeman A, Jones D (2019) Sirolimus: a successful medical treatment for head and neck lymphatic malformations. Case Rep Otolaryngol 2019:2076798. https://doi.org/10.1155/ 2019/2076798.eCollection2019

27. Ghariani Fetoui N, Boussofara L, Gammoudi R, Belajouza C, Ghariani F (2019) A new treatment for vascular anomalies: Six cases treated with rapamycin. Arch Pediatr. 24(7):600–606. https://doi.org/10.1016/j. arcped.2017.04.001

28. Giménez-Alexandre C, Méndez-Aguirre NA, Martínez-Menchón T, Girón-Vallejo O, Fernández-Ibieta M, Ferrí-Níguez B, Villamil V, Sánchez-Sánchez Á, Montoya-Rangel CA, Hernández-Bermejo JP (2019) Nuestra experiencia con la utilización de sirolimus en el tratamiento de anomalías vasculares y linfovasculares [Our experience with sirolimus for the treatment of complicated vascular anomalies]. Cir Pediatr. 32(1):28–33

29. González-Hermosa MR, Guerra E, Tuduri I, Vicente I, López-Almaraz R (2019) CLAPO syndrome: Effective response to treatment with oral rapamycin. Dermatol Ther. 32(4):e12991. https://doi.org/10.1111/ dth.12991

30. Meurisse V, Denamur S, Herbreteau D, Le Touze A, Favrais S, Mester S, Haeberli D, Prokop A, Hanke C, Loichinger W, Quéré I, Baumgartner I, Niemeyer CM, Kapp FG. Severe adverse events during sirolimus "off-label" therapy for vascular anomalies. Pediatr Blood Cancer. 2021:e28936. https://doi.org/10.1002/ pbc.28936

31. Ozeki M, Nozawa A, Yusa S, Endo S, Asada R, Hashimoto H, Fukuo T (2019) The impact of sirolimus therapy on lesion size, clinical symptoms, and quality of life of patients with lymphatic anomalies. Orphanet J Rare Dis 14(1):141. https://doi.org/10.1186/s13023-019-1118-1

32. Pandey V, Tiwari P, Sharma SP, Kumar R, Panigrahi P, Singh OP, Patne S (2019) Development of a biomarker of efficacy in second-line treatment for lymphangiomatosis of the tongue: a pilot study. Br J Oral Maxillofac Surg 57(10):1137–1142. https://doi.org/10.1016/j.bjoms.2019.10.030

33. Sandbank S, Molho-Pessach V, Farkas A, Barzilai A, Greenberger S (2019) Oral and topical sirolimus for vascular anomalies: a multicentre study and review. Acta Derm Venereol 99(1):990–996. https://doi.org/10.2340/00015555-3262

34. Gómez Sánchez A, Redondo Sedano JV, Pérez Alonso V, Martí Carrera ME, Baro Fernández M, Palencia Pérez SI, Gallego Herrera MC, Gómez Fraile A, Delgado Muñoz MD (2020) Oral rapamycin: an alternative in children with complicated vascular abnormalities. Cir Pediatr. 33(4):183–187

35. Honnorat M, Viremouneix L, Ayari S, Guibaud L, Coste K, Claris O, Buitin M (2020) Early adjuvant medication with the mtor inhibitor sirolimus in a preterm neonate with compressive cystic lymphatic malformation. Front Pediatr 8:418. https://doi.org/10. 3389/fped.2020.00418

36. Zhang X, Wang S, Guo Y, Liu Y, Zhang J, Li Y, Liu Q, Liu Z, Sun N, Li X, Liu Y, Du J, Cheng X, Wang X, Tai J, Ni X (2021) Efficacy of initial sirolimus therapy for 27 patients with intractable lymphatic malformations. Laryngoscope 131(8):1902–1908. https://doi.org/10.1002/lary.29419

37. Chouchene F, Masmoudi F, Baaziz A, Maatouk F, Ghedira H (2021) Oral manifestations and dental care management of a young patient with lymphangioma of the tongue: A case report. Clin Case Rep 9(7):e04537. https://doi.org/10.1002/ccr3.4537

38. Harbers VEM, Rongen GAPJM, van der Vleuten CIM, Verhoeven BH, de Laat PCI, van der Horst CMAM, Klein WM, Schultzke Kool LJ, Loo DMWMT. Patients with Congenital Low-Flow Vascular Malformation Treated with Low Dose Sirolimus. Adv Ther. 2021 :38(6):3465–3482. https://doi.org/10.1007/ s12325-021-01758-y

39. Wu C, Song D, Guo L, Wang L (2021) Refractory head and neck lymphatic malformation in infants treated with sirolimus: a case series. Front Oncol 11:616702. https://doi.org/10.3389/fonc.2021.616702

40. Adams DM, Trenor CC 3rd, Hamill AM, Vinks AA, Patel MN, Chaudry G, Wentzel MS, Mobberley-Schuman PS, Campbell LM, Brookbank C, Gupta A, Chute C, Eile J, McKenna J, Merrow AC, Fei L, Hornung L, Seid M, Dasgupta AR, Dickie BH, Elluru RG, Lucky AW, Weiss B, Azizkhan RG (2016) Efficacy and safety of sirolimus in the treatment of complicated vascular anomalies. Pediatrics. 137(2):e20153257

41. Rüssler J, Baselga E, Davila W, Celis V, Diociati A, El Hackem M, Mestre S, Haebert F, Drokop A, Hanke C, Loichinger W, Quéré I, Baumgartner I, Niemeyer CM, Kapp FG. Severe adverse events during sirolimus "off-label" therapy for vascular anomalies. Pediatr Blood Cancer. 2021:e28936. https://doi.org/10.1002/ pbc.28936

42. Horii Y, Ozeki M, Hirose K, Matsuoka K, Matsui T, Kohara M, Tahara S, Toyosawa S, Fukao T, Morii E (2020) Analysis of mTOR pathway expression in lymphatic malformation and related diseases. Pathol Int 70(6):323–329. https://doi.org/10.1111/ pin. 12913

43. Baluk P, Yao LC, Flores JC, Choi D, Hong YK, McDonald DM (2017) Rapamycin reversal of VEGF-C-driven lymphatic anomalies in the respiratory tract. JCI Insight 2:90103

44. Kerjaschki D (2007) How to control lymphangiogenesis: a novel role for rapamycin. Kidney Int 71(8):717–719. https://doi.org/10. 1038/sj.ki.5002184

45. Luo Y, Liu L, Rogers D, Su W, Odaika Y, Zhou H, Alexander JS, Huang S (2012) Rapamycin inhibits lymphatic endothelial cell tube formation by down-regulating vascular endothelial growth factor receptor 3 protein expression. Neoplasia 14:228–237

46. Freixo C, Ferreira V, Martins J, Almeida R, Caldeira D, Rosa M, Costa J, Ferreira J (2020) Efficacy and safety of sirolimus in the treatment of vascular anomalies: A systematic review. J Vasc Surg 71(1):318–327. https://doi.org/10.1016/j. jvs.2019.06.217

47. Russell TB, Rinker EK, Dillingham CS, Ginver LB, Mclean TW (2018) Pneumocystis jirovecii pneumonia during sirolimus therapy of kaposiform hemangioendothelioma. Pediatrics 141(Suppl 5):S421–S424

48. Ying H, Qiao C, Yang Xi, Lin X (2018) A case report of 2 sirolimus-related deaths among infants with kaposiform hemangioendotheliomas. Pediatrics. 141(Suppl 5):S425–S429

49. Shetty AK (2019) Pneumocystis jirovecii pneumonia: A potential complication of sirolimus therapy. J Pediatr Child Health 55:484. https://doi.org/10.1111/jpc.14392

Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.